ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0005

Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease

Thomas Guy1, Hang Liu2, Vinay Mahajan2, Cory Perugino3, Zachary Wallace4, Shauna quinn5, Allen Poma6, Debra Zach7, John Stone8 and Shiv Pillai9, 1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 2Ragon Institute, Cambridge, MA, 3Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5Zenas Biopharma, New York, NY, 6Zenas Biosciences, New York, NY, 7Exagen, Vista, CA, 8Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, 9Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2023

Keywords: B-Cell Targets, IgG4 Related Disease, immunology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0001–0008) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Obexelimab is a bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and ligates FcγRIIb with high affinity. Data from a phase 2 clinical trial of patients with IgG4‑related disease (IgG4-RD), a chronic immune-mediated fibro-inflammatory disease, demonstrated rapid, and sustained clinical improvement, including complete remission in most patients following treatment with obexelimab. Although not shown to drive rapid apoptotic death of B cells, obexelimab treatment does result in an approximate 50% reduction in circulating B cell numbers, as well as near complete reduction in circulating plasmablasts. We have shown that obexelimab dampens the activation of BTK in B cells, easily ascribable to the loss of PIP3 that would result from the predicted activation by FcgRIIb of the SH2-domain containing inositol phosphatase SHIP-1. Here, we aimed to examine the changes in gene expression induced by obexelimab in B cells from treated patients with IgG4-RD to better understand its mechanism of action.

Methods: Peripheral blood was collected from patients with IgG4-RD before and after treatment with obexelimab (two days after the eighth dose). PBMCs were isolated using standard density gradient centrifugation. Naïve (CD19+IgD+CD27–) and memory (CD19+IgD–CD27+) B cell populations were FACS purified and used for subsequent ATAC-sequencing (N = 3 with 3 technical replicates for each sample) and RNA-sequencing (N = 16).

Results: We observed many changes in gene expression and chromatin accessibility attributed to treatment with obexelimab in naïve B cells. RNA sequencing identified 775 genes upregulated and 808 genes downregulated in post- compared to pre-obexelimab treated B cells. ATAC sequencing analysis identified 1040 increased and 708 decreased differentially accessible genes in post- versus pre-obexelimab treated B cells. Gene ontology biological process analysis of ATAC sequencing were consistent with altered cytoskeleton organization, chemotaxis and migration. In addition, nucleotide and purine metabolic processes were impacted after treatment. Furthermore, KEGG pathway analysis demonstrated key components of actin cytoskeleton regulation associated with altered phosphoinositide regulation. Gene ontology biological process analysis of RNA-seq data aligned with ATAC-seq analysis, confirming alteration of cell-cell adhesion and cytoskeletal pathways.

Conclusion: Collectively, these chromatin accessibility and transcriptromic data suggest that reciprocal changes in PIP3 and PI(3,4)P2 dependent events induced by obexelimab on B cells alter B cell activation and migration. Paired with the previous published data demonstrating attenuation of BCR signalling, obexelimab not only reduces PIP3-dependent BCR-induced BTK activation in B cells from IgG4-RD patients but could also enhance PI(3,4 )P2 phosphoinositide-mediated B cell migration, possibly causing sequestration of B cells. Together, these two mechanisms may eliminate the potential of pathogenic, self-reactive B cells to respond to self-antigen, migrate out of secondary lymphoid organs, and infiltrate inflamed tissues.


Disclosures: T. Guy: None; H. Liu: UCB, 3; V. Mahajan: None; C. Perugino: Horizon Therapeutics, 2; Z. Wallace: BioCryst, 2, Bristol-Myers Squibb(BMS), 5, Horizon, 1, 2, 5, MedPace, 2, Novartis, 1, PPD, 2, Sanofi, 1, 5, Shionogi, 1, Visterra, 1, 2, Zenas, 1, 2; S. quinn: Zenas BioPharma, 3, 10, 11; A. Poma: Zenas BioPharma, 3; D. Zach: Exagen, 3, 11; J. Stone: Abvie, 2, Amgen, 1, 2, Argenx, 2, Aztrazeneca, 2, Bristol Myers Squibb, 2, 5, Celgene, 2, Chemocentryx, 2, Chugai, 2, GSK, 2, Horizon Therapeutics, 1, 2, 5, InflaRx, 2, IQVIA, 1, 2, Kyverna, 2, Mirabio, 2, NIH, 5, Novartis, 2, PPD, 2, Prometheus, 2, Q32, 2, Regeneron, 2, Roche-Genentech, 2, Roivant, 2, Sanofi, 2, 5, Spruce Biosciences, 2, Star Therapeutics, 2, Steritas, 12, Chair, Scientific Advisory Board (no fiduciary responsibilities), ZenasBio, 2; S. Pillai: Abpro Inc, 1, BeBio, 1, Octagon Therapeutcis, 1.

To cite this abstract in AMA style:

Guy T, Liu H, Mahajan V, Perugino C, Wallace Z, quinn S, Poma A, Zach D, Stone J, Pillai S. Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/obexelimab-inhibits-b-cell-activation-and-may-interfere-with-b-cell-chemotaxis-in-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obexelimab-inhibits-b-cell-activation-and-may-interfere-with-b-cell-chemotaxis-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology